Part of the special news roundup of DCAT member companies for the DCAT Week ’17 Special Edition of DCAT Value Chain Insights (April 5, 2017)

TA Associates, a Boston-based private equity firm, has completed an investment in Ideal Cures Private Limited, a Mumbai, India-based supplier of ready-to-use coating products and excipients for tablets and capsules to the pharmaceutical and allied industries. Financial terms of the transaction were not disclosed.

Ideal Cures’ products are used to provide aesthetic coatings as well as functional coatings for tablets and capsules. Aesthetic sugar or film coatings allow for swallowability and taste masking while functional coatings serve a number of purposes ranging from moisture, oxygen, and light protection of drugs to controlling drug delivery to a specific part of the gastrointestinal tract. Ideal Cures also produces specialty excipients such as neutral pellets, cooling compounds, taste masking agents, controlled release polymer blends and pharma acrylic polymers.

Ideal Cures has three manufacturing plants in India located in Vasai, Jammu, and Khambat, and two research and development facilities in Mumbai and Vasai. In addition, another plant is under construction in Sikkim.

Ideal Cures’ product portfolio comprises of Instacoat ready-to-use film coating systems, Instanute coating technology for nutraceuticals and dietary supplements, the Ecopol range of pharmaceutical acrylic polymers, the Ecocool brand of cooling compounds, and the Espheres product range of sugar, microcrystalline cellulose, silicon dioxide, calcium carbonate, and tartaric acid spheres.

Source: TA Associates